



## Clinical trial results:

**Pilot trial for the therapy optimisation of children and adolescents with Hodgkin's lymphoma**

**Evaluation of safety of the chemotherapy regimen VECOPA in patients with intermediate or advanced stage disease**

**(Pilotstudie zur Therapieoptimierungsstudie für den Morbus Hodgkin bei Kindern und Jugendlichen. Prüfung der Verträglichkeit der Chemotherapiekombination**

**VECOPA bei Patienten der Therapiegruppen 2 und 3)**

## Summary

EudraCT number	2004-005244-28
Trial protocol	DE
Global end of trial date	31 August 2013

## Results information

Result version number	v1 (current)
This version publication date	04 September 2020
First version publication date	04 September 2020

## Trial information

### Trial identification

Sponsor protocol code	GPOH-HD 2002 Pilot / VECOPA
-----------------------	-----------------------------

### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

## Sponsors

Sponsor organisation name	MLU Halle-Wittenberg
Sponsor organisation address	Magdeburgerstrasse 8, Halle (Saale), Germany,
Public contact	Prof Dr. D. Körholz, MLU Halle-Wittenberg, 0049 345-5572388, dieter.koerholz@medizin.uni-halle.de
Scientific contact	Prof Dr. D. Körholz , MLU Halle-Wittenberg, 0049 345-5572388, dieter.koerholz@medizin.uni-halle.de
Sponsor organisation name	University Leipzig
Sponsor organisation address	Ritterstrasse 26, Leipzig, Germany,
Public contact	Prof Dr. D. Körholz MLU Halle-Wittenberg Ernst-Grube-Strasse 40, 06120 Halle (Saale), Leipzig University, 0049 345-5572388, dieter.koerholz@medizin.uni-halle.de
Scientific contact	Prof Dr. D. Körholz MLU Halle-Wittenberg Ernst-Grube-Strasse 40, 06120 Halle (Saale), Leipzig

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

### Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 February 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 August 2013
Global end of trial reached?	Yes
Global end of trial date	31 August 2013
Was the trial ended prematurely?	No

Notes:

### General information about the trial

Main objective of the trial:

Feasibility and safety of VECOPA instead of standard COPP in male patients with intermediate or advanced stage Hodgkin's lymphoma  
(Kann bei Jungen in den Therapiegruppen 2 und 3 die Kombination VECOPA anstelle des bisher üblichen COPP mit vertretbarer Toxizität eingesetzt werden?)

Protection of trial subjects:

Patients were closely monitored with regard to safety during the course of the study including systematic AE documentation.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	27 May 2005
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

### Population of trial subjects

#### Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 15
Worldwide total number of subjects	15
EEA total number of subjects	15

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	1
Adolescents (12-17 years)	14
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Only subjects who met all inclusion criteria, but none of the exclusion criteria were enrolled.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

No blinding.

### Arms

Arm title	VECOPA
-----------	--------

Arm description:

All patients received two induction cycles of OEPA (standard treatment). Patients with intermediate or advanced stage disease received one or two cycles of VECOPA (experimental).

OEPA cycles consisted of vincristine 1.5 mg/m<sup>2</sup> intravenously (i.v.) on days 1, 8 and 15; etoposide 125 mg/m<sup>2</sup> i.v. on days 3 – 8; prednisone 60 mg/m<sup>2</sup> orally (p.o.) on days 1 – 15; and doxorubicin 40 mg/m<sup>2</sup> i.v. on days 1 and 15

VECOPA consisted of Etoposid 150 mg/m<sup>2</sup> i.v. days 1-3; Adriamycin 25mg/m<sup>2</sup>/i.v. day 21; Vinblastin 6 mg/m<sup>2</sup> i.v. days 1 and 21; Vincristin 1.5 mg/m<sup>2</sup> i.v. days 8 and 29;

Cyclophosphamide 1250 mg/m<sup>2</sup> i.v. days 1 and 21; Prednisone 40 mg/m<sup>2</sup> p.o. days 1-14 and 21-34

Arm type	Experimental
Investigational medicinal product name	Adriblastin
Investigational medicinal product code	Doxorubicin
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

160 - 210 mg/m<sup>2</sup> milligram(s)/sq.meter

Investigational medicinal product name	Vepesid
Investigational medicinal product code	Etoposid
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1050 - to 1950 mg/m<sup>2</sup> milligram(s)/square meter

Investigational medicinal product name	Etopophos
Investigational medicinal product code	Etoposide phosphate
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:	
1207,5 - to 2242,5 mg/m2 milligram(s)/square meter	
Investigational medicinal product name	Vincristin Bristol
Investigational medicinal product code	Vincristin
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
9 - to 15 mg/m2 milligram(s)/square meter	
Investigational medicinal product name	Vinblastinsulfat-GRY
Investigational medicinal product code	Vinblastin
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
12 - to 24 UIntrmg/m2 milligram(s)/square meter	
Investigational medicinal product name	Endoxan
Investigational medicinal product code	Cyclophosphamide
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
2500 - 5000 mg/m2 milligram(s)/square meter	
Investigational medicinal product name	Uromitexan
Investigational medicinal product code	Mesna
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
3300 - to 6600 mg/m2 milligram(s)/square meter	
Investigational medicinal product name	Prednison-ratiopharm
Investigational medicinal product code	Prednisone
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
2920 - to 4040 mg/m2 milligram(s)/square meter	
Investigational medicinal product name	Granocyte
Investigational medicinal product code	Lenograstim
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
40 - to 160 µg/m2 microgram(s)/square meter	

<b>Number of subjects in period 1</b>	VECOPA
Started	15
Completed	14
Not completed	1
Lack of efficacy	1

## Baseline characteristics

### Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	15	15	
Age categorical			
Units: Subjects			
Children (2-11 years)	1	1	
Adolescents (12-17 years)	14	14	
Age continuous			
Units: years			
median	15.3		
full range (min-max)	8.2 to 17.8	-	
Gender categorical			
Units: Subjects			
Male	15	15	
Stage			
Units: Subjects			
intermediate	4	4	
advanced	11	11	

## End points

### End points reporting groups

Reporting group title	VECOPA
-----------------------	--------

Reporting group description:

All patients received two induction cycles of OEPA (standard treatment). Patients with intermediate or advanced stage disease received one or two cycles of VECOPA (experimental).

OEPA cycles consisted of vincristine 1.5 mg/m<sup>2</sup> intravenously (i.v.) on days 1, 8 and 15; etoposide 125 mg/m<sup>2</sup> i.v. on days 3 – 8; prednisone 60 mg/m<sup>2</sup> orally (p.o.) on days 1 – 15; and doxorubicin 40 mg/m<sup>2</sup> i.v. on days 1 and 15

VECOPA consisted of Etoposid 150 mg/m<sup>2</sup> i.v. days 1-3; Adriamycin 25mg/m<sup>2</sup>/i.v. day 21; Vinblastin 6 mg/m<sup>2</sup> i.v. days 1 and 21; Vincristin 1.5 mg/m<sup>2</sup> i.v. days 8 and 29;

Cyclophosphamide 1250 mg/m<sup>2</sup> i.v. days 1 and 21; Prednisone 40 mg/m<sup>2</sup> p.o. days 1-14 and 21-34

### Primary: Feasibility of VECOPA

End point title	Feasibility of VECOPA <sup>[1]</sup>
-----------------	--------------------------------------

End point description:

Rate of VECOPA cycles in which recovery of blood counts on day 21 and 42 was sufficient to allow continuation of therapy (i.e. leukocytes  $\geq 1,8 \times 10^9 / l$  and thrombocytes  $\geq 50 \times 10^9 / l$  and no active infection)

We analysed cycles. 26 of 26 cycles were given in full dose.

The primary endpoint required valid blood counts available for 21cycles.

End point type	Primary
----------------	---------

End point timeframe:

after end of VECOPA therapy

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This is a single arm trial. Reporting of statistical analyses in this database require at least two arms, otherwise an error message occurs.

End point values	VECOPA			
Subject group type	Reporting group			
Number of subjects analysed	14 <sup>[2]</sup>			
Units: cycles	16			

Notes:

[2] - We report on 21 of 26 cycles (cycles with valid blood counts only).

### Statistical analyses

No statistical analyses for this end point



---

**Secondary: Event free survival (EFS)**

---

End point title	Event free survival (EFS)
-----------------	---------------------------

End point description:

EFS was defined as the time from the start of treatment until the first of the following events: progression/ relapse of disease, diagnosis of a secondary malignancy or death from any cause.

End point type	Secondary
----------------	-----------

End point timeframe:

36 months after inclusion

---

End point values	VECOPA			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: rate				
number (confidence interval 95%)	0.857 (0.692 to 1)			

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From inclusion to up to 4 weeks after the last dose of chemotherapy

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

### Reporting groups

Reporting group title	All patients
-----------------------	--------------

Reporting group description: -

<b>Serious adverse events</b>	All patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 15 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	All patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 15 (100.00%)		
Investigations			
White blood cell count			
subjects affected / exposed	15 / 15 (100.00%)		
occurrences (all)	65		
Granulocyte count			
subjects affected / exposed	15 / 15 (100.00%)		
occurrences (all)	54		
Haemoglobin			
subjects affected / exposed	14 / 15 (93.33%)		
occurrences (all)	45		
Hepatic enzyme			
subjects affected / exposed	14 / 15 (93.33%)		
occurrences (all)	35		

Body temperature subjects affected / exposed occurrences (all)	8 / 15 (53.33%) 10		
Platelet count subjects affected / exposed occurrences (all)	5 / 15 (33.33%) 9		
Blood bilirubin subjects affected / exposed occurrences (all)	3 / 15 (20.00%) 6		
Blood creatinine subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 5		
Pulmonary function test subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 5		
Injury, poisoning and procedural complications Radiation associated pain subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 2		
Nervous system disorders Motor dysfunction subjects affected / exposed occurrences (all)  Sensory disturbance subjects affected / exposed occurrences (all)  Headache subjects affected / exposed occurrences (all)	4 / 15 (26.67%) 10  3 / 15 (20.00%) 8  1 / 15 (6.67%) 2		
General disorders and administration site conditions Mucosal inflammation subjects affected / exposed occurrences (all)	11 / 15 (73.33%) 21		
Eye disorders Eye inflammation			

subjects affected / exposed occurrences (all)	3 / 15 (20.00%) 3		
Gastrointestinal disorders			
Vomiting			
subjects affected / exposed	9 / 15 (60.00%)		
occurrences (all)	18		
Constipation			
subjects affected / exposed	8 / 15 (53.33%)		
occurrences (all)	13		
Diarrhoea			
subjects affected / exposed	8 / 15 (53.33%)		
occurrences (all)	9		
Dysphagia			
subjects affected / exposed	7 / 15 (46.67%)		
occurrences (all)	8		
Dyspepsia			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	2		
Salivary gland disorder			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Skin disorder			
subjects affected / exposed	2 / 15 (13.33%)		
occurrences (all)	3		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	2		
Infections and infestations			
Infection			
subjects affected / exposed	8 / 15 (53.33%)		
occurrences (all)	12		
Herpes labialis			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	2		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/25204374>